S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:PMD

Psychemedics - PMD Stock Forecast, Price & News

$5.72
+0.09 (+1.60%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.71
$5.75
50-Day Range
$5.70
$6.66
52-Week Range
$5.61
$8.00
Volume
8,044 shs
Average Volume
10,382 shs
Market Capitalization
$32.29 million
P/E Ratio
N/A
Dividend Yield
4.91%
Price Target
N/A

Psychemedics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.20% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.32mentions of Psychemedics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.42 out of 5 stars

Medical Sector

997th out of 1,047 stocks

Medical Laboratories Industry

25th out of 26 stocks

PMD stock logo

About Psychemedics (NASDAQ:PMD) Stock

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

PMD Stock News Headlines

Psychemedics Co. (PMD) To Go Ex-Dividend on December 1st
Psychemedics: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

PMD Company Calendar

Last Earnings
4/23/2019
Ex-Dividend for 9/9 Dividend
8/23/2022
Dividend Payable
9/09/2022
Today
12/01/2022
Ex-Dividend for 12/16 Dividend
12/01/2022
Dividend Payable
12/16/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PMD
Employees
139
Year Founded
1985

Profitability

Net Income
$-670,000.00
Pretax Margin
-10.53%

Debt

Sales & Book Value

Annual Sales
$24.91 million
Cash Flow
$0.54 per share
Book Value
$2.08 per share

Miscellaneous

Free Float
4,872,000
Market Cap
$32.29 million
Optionable
Not Optionable
Beta
0.53

Social Links


Key Executives

  • Mr. Raymond C. Kubacki (Age 77)
    Chairman, CEO & Pres
    Comp: $473.2k
  • Mr. Charles M. Doucot IV (Age 56)
    Exec. VP
    Comp: $262.75k
  • Dr. Michael I. Schaffer Ph.D. (Age 77)
    VP of Laboratory Operations
    Comp: $248.02k
  • Dr. Werner A. Baumgartner Ph.D.
    Founder
  • Ms. Annette Baumgartner
    Founder
  • Ms. Sarah Ashby
    VP & Gen. Counsel
  • Mr. Patrick J. Kinney Jr.
    Sec.













PMD Stock - Frequently Asked Questions

How have PMD shares performed in 2022?

Psychemedics' stock was trading at $7.02 at the start of the year. Since then, PMD stock has decreased by 18.5% and is now trading at $5.72.
View the best growth stocks for 2022 here
.

When is Psychemedics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our PMD earnings forecast
.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) issued its quarterly earnings data on Tuesday, April, 23rd. The company reported $0.11 earnings per share for the quarter. The company earned $9.82 million during the quarter. Psychemedics had a negative net margin of 7.77% and a negative trailing twelve-month return on equity of 16.68%.

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Wednesday, November 9th. Shareholders of record on Friday, December 2nd will be given a dividend of $0.07 per share on Friday, December 16th. This represents a $0.28 annualized dividend and a yield of 4.90%. The ex-dividend date is Thursday, December 1st.
Read our dividend analysis for PMD
.

Is Psychemedics a good dividend stock?

Psychemedics (NASDAQ:PMD) pays an annual dividend of $0.28 per share and currently has a dividend yield of 4.91%. PMD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for PMD.

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.44%) and Wedbush Securities Inc. (0.35%). Insiders that own company stock include Fred J Weinert, Michael I Schaffer, Peter Kamin and Raymond C Kubacki Jr.
View institutional ownership trends
.

How do I buy shares of Psychemedics?

Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $5.72.

How much money does Psychemedics make?

Psychemedics (NASDAQ:PMD) has a market capitalization of $32.29 million and generates $24.91 million in revenue each year. The company earns $-670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Psychemedics have?

The company employs 139 workers across the globe.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The official website for the company is www.psychemedics.com. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236.

This page (NASDAQ:PMD) was last updated on 12/2/2022 by MarketBeat.com Staff